Mitochondria and Mood: Mitochondrial Dysfunction as a Key Player in the Manifestation of Depression.

Allen J, Romay-Tallon R, Brymer KJ, Caruncho HJ, Kalynchuk LE. · 2018

Read Mitochondria and Mood: Mitochondrial Dysfunction as a Key Player in the Manifestation of Depression. by Allen J, Romay-Tallon R, Brymer KJ, Caruncho HJ, Kalynchuk LE. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5997778.txt.

Introduction

Allen and co-authors make the case that mitochondrial dysfunction is a key player in depression. Their paper appeared in Frontiers in Neuroscience. Depression was long tied to monoamine changes and neuron growth. New data point to wider losses of cell plasticity. Mitochondria power the cell and steer brain function. They also drive oxidative stress and apoptosis. Faults in their energy work may precede depressive symptoms.

Drug data on mitochondria point both ways, the authors note. Some antidepressants help them, others worsen their state. The link still deserves deeper study, they argue. Mitochondria could be targets for new antidepressant drugs. Specific faults might serve as personal treatment markers.

Catalog record

CREATORAllen J, Romay-Tallon R, Brymer KJ, Caruncho HJ, Kalynchuk LE.
YEAR2018
COLLECTIONPAPERS
FORMATTXT
FILE SIZE83 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5997778

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Mitochondria and Mood: Mitochondrial Dysfunction as a Key Player in the Manifestation of Depression By Josh Allen, Raquel Romay-Tallon, Kyle J Brymer, Hector J Caruncho, Lisa E Kalynchuk Published in: Frontiers in Neuroscience DOI: 10.3389/fnins.2018.00386 ABSTRACT Abstract Human and animal studies suggest an intriguing link between mitochondrial diseases and depression. Although depression has historically been linked to alterations in monoaminergic pharmacology and adult hippocampal neurogenesis, new data increasingly implicate broader forms of dampened plasticity, including plasticity within the cell. Mitochondria are the cellular powerhouse of eukaryotic cells, and they also regulate brain function through oxidative stress and apoptosis. In this paper, we make the case that mitochondrial dysfunction could play an important role in the pathophysiology of depression. Alterations in mitochondrial functions such as oxidative phosphorylation (OXPHOS) and membrane polarity, which increase oxidative stress and apoptosis, may precede the development of depressive symptoms. However, the data in relation to antidepressant drug effects are contradictory: some studies reveal they have no effect on mitochondrial function or even potentiate dysfunction, whereas other studies show more beneficial effects. Overall, the data suggest an intriguing link between mitochondrial function and depression that warrants further investigation. Mitochondria could be targeted in the development of novel antidepressant drugs, and specific forms of mitochondrial dysfunction could be identified as biomarkers to personalize treatment and aid in early diagnosis by differentiating between disorders with overlapping symptoms. Keywords: depression, behavior, reelin, mitochondria, oxidative phosphorylation, antidepressants MITOCHONDRIA Mitochondria are the main energy factories of eukaryotic cells. The brain is particularly dependent on mitochondrial activity due to both its high levels of energy use and its inability to store large amounts of energy reserves in the form of glycogen. As a result of the their roles in energy production, mitochondria also generate reactive oxygen species (ROS) that may have a toxic effects in cells. In addition, mitochondria also play a prominent role in the regulation of apoptotic cell death (for examples, see Davidson and Hardison, 1984; Herrmann and Neupert, 2000; Calabrese et al., 2001; Chan, 2006; Chipuk et al., 2006; Fattal et al., 2006; McBride et al., 2006; Youle and van der Bliek, 2012; Tobe, 2013; Bansal and Kuhad, 2016). The focus of this review is the link between mitochondrial dysfunction and major depression. Depression has historically been considered a disorder of altered pharmacology and altered hippocampal neurogenesis. However, recent evidence has opened the door to an expanded notion of the neurobiology of depression, such that a reduction in ATP levels, enhancement of oxidative stress, and acceleration of apoptosis are now considered to be important events (reviewed in Rezin et al., 2008a). In this review, we summarize some of the latest knowledge on mitochondrial dysregulation in major depression (depicted in Figure 1) and also discuss how mitochondrial dysfunction could instigate downstream changes in extracellular matrix proteins such as reelin, neuronal nitric oxide (nNOS), oxidative stress, and inflammation, and finally adult hippocampal neurogenesis. Uncovering how all these factors influence one another could lead to new vistas in the development of novel therapeutics for the treatment of this problematic disorder. [Figure: The mitochondrion under normal physiological conditions and in the depression brain. As detailed in the right side of the image, there are a series of mitochondrial alterations that have been observed both in depressed patients and in animal models of depression (red lines). These include changes affecting mitochondrial DNA, membrane permeability, and increased formation of reactive oxygen species (ROS). As a consequence, these alterations lead to pro-inflammatory activity, increased apoptosis, and dampened synaptic plasticity and neuronal differentiation. Interestingly, antidepressant medication can restore the mitochondrial oxidant/antioxidant balance, and therefore help to rescue the negative effects of mitochondrial dysregulation (green lines). See the text for more detailed explanations.] HYPOTHESES ABOUT THE NEUROBIOLOGICAL BASIS OF DEPRESSION Depression is a common neuropsychiatric disorder, affecting up to 20% of the population (Kessler et al., 1994). The presence and severity of symptoms vary among individuals, and can include low mood and anhedonia, decreased energy, altered appetite and weight, irritability, sleep disturbances, and cognitive deficits (Nemeroff, 1998). Patients with depression have a higher rate of other physical illnesses (i.e., comorbidities with cardiovascular disorders, stroke, etc.), decreased social functioning, and a high mortality rate (Nemeroff, 1998). The complexity of this disorder is further compounded by the fact that it often co-occurs with other psychiatric conditions. For example, about 50% of depression patients also suffer from anxiety disorders (Kessler et al., 1996), which can indicate a more severe form of the disease, with delayed recovery, increased risk of relapse, greater disability, and increased suicide attempts (Hirschfeld, 2001). It is generally thought that a combination of environmental and genetic factors influences the development of depression (Nestler et al., 2002; Kalia, 2005). However, despite extensive clinical and preclinical research efforts, there is still a fundamental lack of understanding about the specific biological changes that give rise to depressive symptoms. For more than 50 years, the dominant theory for the pathogenesis of depression was the monoamine hypothesis (Schildkraut, 1965), which arose from observations that antidepressant drugs work by inhibiting the reuptake of monoamines such as serotonin and norepinephrine. However, this theory has largely fallen out of favor due to a number of discrepancies, such as the fact that the therapeutic effects of antidepressants take weeks to develop even though monoamine levels are elevated within hours of administration, and the fact that only about 40% of patients respond satisfactorily to treatment (Trivedi et al., 2006). More recent theories about the neurobiological basis of depression have focused on the neurogenesis theory, which posits that stress-induced decreases in hippocampal neurogenesis could be a causal factor in depression (Jacobs et al., 2000). This hypothesis is supported by observations of decreased hippocampal volume in patients with depression (MacQueen et al., 2003; Campbell et al., 2004), decreased cell proliferation and survival in preclinical animal models of depression (Brummelte and Galea, 2010; Schoenfeld and Cameron, 2015), and increased cell proliferation and survival after antidepressant treatment (Santarelli et al., 2003; Fenton et al., 2015). Our laboratory has contributed to this literature using a well-validated preclinical model of depression in which rats or mice are subjected to daily injections of the stress hormone corticosterone (CORT) for several weeks, followed by behavioral testing and then tissue collection for further analyses (Gregus et al., 2005; Johnson et al., 2006; Sterner and Kalynchuk, 2010). Using this approach, we showed that the time course for the onset of depression-like behavior in rats is paralleled by dampened hippocampal neurogenesis and neuronal maturation (Lussier et al., 2013). Importantly, this work also implicated the extracellular matrix protein reelin in the pathogenesis of depression (see Caruncho et al., 2016). There is evidence that reelin can regulate adult hippocampal neurogenesis and dendritic spine plasticity (Pujadas et al., 2010), and our data show that rats subjected to repeated CORT injections have dampened reelin expression selectively in the proliferative subgranular zone of the dentate gyrus (Lussier et al., 2009) and also that antidepressant treatment normalizes depression-like behavior, hippocampal neurogenesis, and hippocampal reelin expression in tandem (Fenton et al., 2015). The reelin link is relevant to mitochondrial dysfunction because reelin in the periphery interacts with the immune system and a loss of reelin can magnify markers of inflammation that influence mitochondria (Green-Johnson et al., 1995).

Read the complete text